

HIV Prevention Product Overview

Product	Yearly Dosage	Frequency, Volume, Delivery Site, Drug Class	Efficacy, Efficacy Date	Developer, Regulatory, Generics	LMIC Price PPPY
Oral PrEP (TDF/FTC) (TDF/xTC) (F/TAF)		<p>One pill every day; event-driven dosing of 2-1-1 for cisgender men (TDF/FTC only)</p> <p>TDF/FTC: Oral tablet-200mg FTC, 300mg TDF</p> <p>F/TAF: Oral tablet - 200mg FTC, 25mg TAF</p> <p>Nucleoside reverse transcriptase inhibitor (NRTI)</p>	 <p>TDF/FTC - 2010 All populations ($\pm 90\%$ with 7 doses/week); highly adherent-dependent</p> <p>F/TAF - 2011 Cisgender men & TG women ($\pm 90\%$ with 7 doses/week); highly adherent-dependent; PURPOSE 1 trial evaluating use in cisgender women, results expected 2027</p>	<p>Gilead Sciences >100 approvals WHO recommended in 2015 15+ suppliers globally</p>	±\$40
Dapivirine Vaginal Ring (DVR)		<p>One ring every month</p> <p>One 25mg dapivirine vaginal ring</p> <p>Non-nucleoside reverse transcriptase inhibitor (NNRTI)</p>	 <p>DVR - 2016 Cisgender women (35% risk reduction in efficacy trials; 50%+ reduction with consistent use in Open Label Extension studies; highly adherent-dependent)</p>	<p>IPM / PopCouncil 11 approvals WHO recommended in 2021 MOU with Kiara in South Africa; license and timelines TBD</p>	\$71
Injectable Cabotegravir (CAB)	<p>Day 1 (Month 0) </p> <p>Month 1 </p> <p>Month 3 </p> <p>Month 5 </p> <p>Month 7 </p> <p>Month 9 </p> <p>Month 11 </p>	<p>First injection on day 1, second injection 1 month later, then every 2 months</p> <p>One 3 mL intramuscular injection in gluteal muscle (buttocks)</p> <p>Integrase strand transfer inhibitor (INSTI)</p>	 <p>CAB - 2020 All populations (89% higher effectiveness in cisgender women and 66% in MSM and TG women, compared to oral PrEP)</p>	<p>Viiv Healthcare 30 approvals WHO recommended in 2022 3 licenses via MPP, expected earliest market access in 2027</p>	≈\$160 (set in GBP; USD subject to currency fluctuations)
Injectable Lenacapavir (LEN)	<p>Day 1 (Month 0) * </p> <p>Day 2 (Month 0) * </p> <p>Month 6 </p> <p>Month 12 </p> <p><small>*Oral tablets taken only at time of initiation/ re-start</small></p>	<p>First injection and two oral tablets on day 1, two oral tablets on day 2, then injections every 6 months</p> <p>Two 1.5 mL subcutaneous injections in abdomen and four 300mg lenacapavir tablets</p> <p>Capsid inhibitor</p>	 <p>LEN - 2024 All populations (100% efficacy in cisgender women, 96% reduction compared to background HIV incidence in cisgender men and TG and GNB people)</p>	<p>Gilead Sciences 14 approvals WHO recommended in 2025 6 direct licenses, expected earliest market access in 2027</p>	<p>Originator price not public, assumed \$100. Generic price (2027) \$40 PPPY plus \$15-17 for oral loading dose</p>

LMIC = low- and middle-income country; PPPY = per person per year; TG = transgender; MSM = men who have sex with men; GNB = gender nonbinary